VBI Vaccines Inc (TSE:VBV) Director Jeffrey Royston Baxter acquired 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average price of C$3.22 per share, with a total value of C$32,200.00.

Shares of VBI Vaccines Inc (TSE VBV) traded down 0.47% during mid-day trading on Friday, reaching $4.28. The company had a trading volume of 2,217 shares. VBI Vaccines Inc has a 52-week low of $3.61 and a 52-week high of $8.94. The company’s market cap is $172.18 million. The firm’s 50-day moving average price is $5.24 and its 200 day moving average price is $6.03.

WARNING: “VBI Vaccines Inc (VBV) Director Buys C$32,200.00 in Stock” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/26/vbi-vaccines-inc-vbv-director-buys-c32200-00-in-stock.html.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process.

Receive News & Stock Ratings for VBI Vaccines Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc and related stocks with our FREE daily email newsletter.